Form 8K Arbutus Biopharma Corp For: 6 August
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Arbutus Biopharma Corp (ABUS)
Arbutus Biopharma Corp stock price live, this page displays NASDAQ ABUS stock exchange data. View the ABUS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Arbutus Biopharma Corp real time stock price chart below.
What Is the Arbutus Biopharma Corp Stock Price Today?
The Arbutus Biopharma Corp stock price today is 3.365.
What Is the Stock Symbol for Arbutus Biopharma Corp?
The stock symbol for Arbutus Biopharma Corp is ""ABUS.""
What Stock Exchange Does Arbutus Biopharma Corp Trade On?
Arbutus Biopharma Corp is listed and trades on the NASDAQ stock exchange.
Is Arbutus Biopharma Corp a Good Stock to Buy?
Determining whether Arbutus Biopharma Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ABUS quote. (ISIN: CA03879J1003)
What Is the Arbutus Biopharma Corp Stock Price Today?
The Arbutus Biopharma Corp stock price today is 3.365.
What Is the Stock Symbol for Arbutus Biopharma Corp?
The stock symbol for Arbutus Biopharma Corp is ""ABUS.""
What Stock Exchange Does Arbutus Biopharma Corp Trade On?
Arbutus Biopharma Corp is listed and trades on the NASDAQ stock exchange.
Is Arbutus Biopharma Corp a Good Stock to Buy?
Determining whether Arbutus Biopharma Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ABUS quote. (ISIN: CA03879J1003)
Currency in USD
Fair Value
An estimate of a Arbutus Biopharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.310
3.450
52 wk Range
2.705
4.725
ABUS Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
ABUS is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Arbutus Biopharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.3103.450
52 wk Range
2.7054.725
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ABUS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Arbutus Biopharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PricePrice Target
5.224
Upside
+55.25%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
- Form 8K Arbutus Biopharma Corp For: 23 May
- Investing.com
- Form 8K Arbutus Biopharma Corp For: 25 June
- Investing.com
- Form 8K Arbutus Biopharma Corp For: 6 August
- Investing.com
- Form 8K Arbutus Biopharma Corp For: 25 June
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Sell
Moving Averages
Buy
Arbutus Biopharma Corp Company Profile
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Arbutus Biopharma Corp SWOT Analysis
Hepatitis B Focus | Arbutus Biopharma streamlines operations to concentrate on imdusiran, its lead siRNA candidate for chronic hepatitis B treatment, extending financial runway |
Clinical Promise | Explore imdusiran's potential as revealed in the IM-PROVE I trial, showcasing efficacy in combination therapies and a favorable safety profile |
Financial Stability | Delve into Arbutus's robust cash position of $148.5 million, with liquid assets exceeding short-term obligations by 7x, supporting operations through 2026 |
Market Potential | Analyst targets range from $3.91 to $6.89, reflecting optimism in Arbutus's potential to capture significant market share in the competitive CHB treatment landscape |
Arbutus Biopharma Corp Earnings Call Summary for Q2/2024
- Positive Phase 2a data for imdusiran in hepatitis B treatment; Phase 2b development planned
- 40% workforce reduction to streamline operations and extend cash runway through Q4 2026
- $148.5 million cash balance; sufficient to fund upcoming Phase 2b trial
- Litigation update: trial with Moderna and Pfizer/BioNTech set for April 21, 2025
- Considering focus on patients with baseline HBsAg levels below 1,000 for higher response rates
Last Updated: 01/08/2024, 21:50
Read Full TranscriptCompare ABUS to Peers and Sector
Metrics to compare | ABUS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipABUSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −11.9x | −3.5x | −0.5x | |
PEG Ratio | −0.34 | −0.03 | 0.00 | |
Price/Book | 7.8x | 1.8x | 2.6x | |
Price / LTM Sales | 41.8x | 5.8x | 3.3x | |
Upside (Analyst Target) | 47.6% | 114.8% | 40.3% | |
Fair Value Upside | Unlock | −1.9% | 5.1% | Unlock |
Analyst Ratings
3 Buy
1 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 5.224
(+55.25% Upside)
Earnings
Latest Release
Aug 06, 2025
EPS / Forecast
0.01 / -0.04
Revenue / Forecast
10.74M / 1.61M
People Also Watch
FAQ
What Stock Exchange Does Arbutus Biopharma Trade On?
Arbutus Biopharma is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Arbutus Biopharma?
The stock symbol for Arbutus Biopharma is "ABUS."
What Is the Arbutus Biopharma Market Cap?
As of today, Arbutus Biopharma market cap is 645.07M.
What Is Arbutus Biopharma's Earnings Per Share (TTM)?
The Arbutus Biopharma EPS (TTM) is -0.29.
When Is the Next Arbutus Biopharma Earnings Date?
Arbutus Biopharma will release its next earnings report on 04 Nov 2025.
From a Technical Analysis Perspective, Is ABUS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
How Many Times Has Arbutus Biopharma Stock Split?
Arbutus Biopharma has split 0 times.
How Many Employees Does Arbutus Biopharma Have?
Arbutus Biopharma has 44 employees.
What is the current trading status of Arbutus Biopharma (ABUS)?
As of 16 Aug 2025, Arbutus Biopharma (ABUS) is trading at a price of 3.37, with a previous close of 3.37. The stock has fluctuated within a day range of 3.31 to 3.45, while its 52-week range spans from 2.71 to 4.73.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.